Sagimet updates investor presentation highlighting MASH, acne, and cancer pipeline

Sagimet Biosciences Inc.

Presentation dated October 23, 2025, targets metabolic dysfunction with novel therapies for MASH, acne, and cancer.
Management will use the updated deck in investor meetings; specific data or milestones not disclosed in filing excerpt.
No financial results, guidance changes, or clinical trial readouts included in the furnished exhibit (title page only).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.